RXRA and adenocarcinoma: Reduced tumor diversity and tumor size; suppressed the level of leukotriene B4, proinflammatory eicosanoids and prostaglandin E2 in plasma; decreased the nuclear expression of β-catenin; induced cell apoptosis; and increased the expression level of RXRα, β, and γ in adenocarcinoma